MFN

News

White House signs pricing deals with nine more pharmas

Nine mid-sized pharmas have signed up for the Trump administration's Most-Favoured Nation (MFN) pricing deals, pledging almost $20bn in investments.

Market Access

The new commercialisation playbook: What BIO 2026 taught eme...

BIO International focused on how emerging biotech companies should approach their first product launch outside the United States, typically in Europe.

News

MFN affecting Swiss medicines access, says Interpharma

Pharma groups have held back from submitting around a third of their new medicines for reimbursement in Switzerland, impeding patient access.

Oncology

How IRA, MFN, and HTA are rewriting oncology launch strategy...

Market Access

MFN and TrumpRx: What’s the real impact for the American con...

News

AbbVie makes record investment in North Carolina plant

AbbVie's $100bn programme of facility investments in the US has continued with a new 185-acre campus in Durham, North Carolina.

White House signs pricing deals with nine more pharmas

The new commercialisation playbook: What BIO 2026 taught eme...

MFN affecting Swiss medicines access, says Interpharma

How IRA, MFN, and HTA are rewriting oncology launch strategy...

MFN and TrumpRx: What’s the real impact for the American con...

AbbVie makes record investment in North Carolina plant

Merck rare tumour drug Ezmekly backed for NHS use

Discover a new era of healthcare panel engagement: Grounded ...

MFN

Editor's Picks